Cargando…

Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors

The angiotensin-converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase, which has a direct involvement in the control of blood pressure by performing the hydrolysis of angiotensin I to produce angiotensin II. At the same time, ACE hydrolyzes other substrates such as the vasodilator pepti...

Descripción completa

Detalles Bibliográficos
Autor principal: Caballero, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024173/
https://www.ncbi.nlm.nih.gov/pubmed/31940798
http://dx.doi.org/10.3390/molecules25020295
_version_ 1783498373658050560
author Caballero, Julio
author_facet Caballero, Julio
author_sort Caballero, Julio
collection PubMed
description The angiotensin-converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase, which has a direct involvement in the control of blood pressure by performing the hydrolysis of angiotensin I to produce angiotensin II. At the same time, ACE hydrolyzes other substrates such as the vasodilator peptide bradykinin and the anti-inflammatory peptide N-acetyl-SDKP. In this sense, ACE inhibitors are bioactive substances with potential use as medicinal products for treatment or prevention of hypertension, heart failures, myocardial infarction, and other important diseases. This review examined the most recent literature reporting ACE inhibitors with the help of molecular modeling. The examples exposed here demonstrate that molecular modeling methods, including docking, molecular dynamics (MD) simulations, quantitative structure-activity relationship (QSAR), etc, are essential for a complete structural picture of the mode of action of ACE inhibitors, where molecular docking has a key role. Examples show that too many works identified ACE inhibitory activities of natural peptides and peptides obtained from hydrolysates. In addition, other works report non-peptide compounds extracted from natural sources and synthetic compounds. In all these cases, molecular docking was used to provide explanation of the chemical interactions between inhibitors and the ACE binding sites. For docking applications, most of the examples exposed here do not consider that: (i) ACE has two domains (nACE and cACE) with available X-ray structures, which are relevant for the design of selective inhibitors, and (ii) nACE and cACE binding sites have large dimensions, which leads to non-reliable solutions during docking calculations. In support of the solution of these problems, the structural information found in Protein Data Bank (PDB) was used to perform an interaction fingerprints (IFPs) analysis applied on both nACE and cACE domains. This analysis provides plots that identify the chemical interactions between ligands and both ACE binding sites, which can be used to guide docking experiments in the search of selective natural components or novel drugs. In addition, the use of hydrogen bond constraints in the S(2) and S(2)′ subsites of nACE and cACE are suggested to guarantee that docking solutions are reliable.
format Online
Article
Text
id pubmed-7024173
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70241732020-03-19 Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors Caballero, Julio Molecules Review The angiotensin-converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase, which has a direct involvement in the control of blood pressure by performing the hydrolysis of angiotensin I to produce angiotensin II. At the same time, ACE hydrolyzes other substrates such as the vasodilator peptide bradykinin and the anti-inflammatory peptide N-acetyl-SDKP. In this sense, ACE inhibitors are bioactive substances with potential use as medicinal products for treatment or prevention of hypertension, heart failures, myocardial infarction, and other important diseases. This review examined the most recent literature reporting ACE inhibitors with the help of molecular modeling. The examples exposed here demonstrate that molecular modeling methods, including docking, molecular dynamics (MD) simulations, quantitative structure-activity relationship (QSAR), etc, are essential for a complete structural picture of the mode of action of ACE inhibitors, where molecular docking has a key role. Examples show that too many works identified ACE inhibitory activities of natural peptides and peptides obtained from hydrolysates. In addition, other works report non-peptide compounds extracted from natural sources and synthetic compounds. In all these cases, molecular docking was used to provide explanation of the chemical interactions between inhibitors and the ACE binding sites. For docking applications, most of the examples exposed here do not consider that: (i) ACE has two domains (nACE and cACE) with available X-ray structures, which are relevant for the design of selective inhibitors, and (ii) nACE and cACE binding sites have large dimensions, which leads to non-reliable solutions during docking calculations. In support of the solution of these problems, the structural information found in Protein Data Bank (PDB) was used to perform an interaction fingerprints (IFPs) analysis applied on both nACE and cACE domains. This analysis provides plots that identify the chemical interactions between ligands and both ACE binding sites, which can be used to guide docking experiments in the search of selective natural components or novel drugs. In addition, the use of hydrogen bond constraints in the S(2) and S(2)′ subsites of nACE and cACE are suggested to guarantee that docking solutions are reliable. MDPI 2020-01-11 /pmc/articles/PMC7024173/ /pubmed/31940798 http://dx.doi.org/10.3390/molecules25020295 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caballero, Julio
Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title_full Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title_fullStr Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title_full_unstemmed Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title_short Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
title_sort considerations for docking of selective angiotensin-converting enzyme inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024173/
https://www.ncbi.nlm.nih.gov/pubmed/31940798
http://dx.doi.org/10.3390/molecules25020295
work_keys_str_mv AT caballerojulio considerationsfordockingofselectiveangiotensinconvertingenzymeinhibitors